Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEVA trial of dequalinium versus usual care antibiotics for bacterial vaginosis
2019-002819-25Phase 4Unknown
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Feb 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dequalinium, metronidazole, clindamycin and tinidazole in bacterial vaginosis (BV) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Participant-reported resolution of bacterial vaginosis symptoms at 4 weeks without additional treatment. Status: unknown.
02
Drugs
dequaliniummetronidazoleclindamycintinidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on 2019-002819-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002819-25.